BCT BriaCell Therapeutics Corp

BriaCell to Present Clinical Findings at the 2020 San Antonio Breast Cancer Symposium®, December 9 – 11

BriaCell to Present Clinical Findings at the 2020 San Antonio Breast Cancer Symposium®, December 9 – 11
EN
06/10/2020

Underlying

BCTBriaCell Therapeutics Corp

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BriaCell Therapeutics Corp

 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction fo...

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License PHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced the completion of the previously announced asset purchase transaction (the “Transaction”) pursuant to a definitive purchase agreem...

March 31, 2026 1 EN
 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinic...

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it will present four posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22 at the San Dieg...

March 18, 2026 1 EN
 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual ...

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting PHILADELPHIA and VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that four abstracts have been accepted for poster presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place from April 17th – 22nd at San Diego Convention Center, San Diego, CA. The acce...

March 10, 2026 1 EN
 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the “Shareholders”) for the year ended July 31, 2025 held on March 5, 2026 (the “Meeting”). A total of 48.31% of the Company’s issued and outsta...

March 5, 2026 1 EN
 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive...

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License PHILADELPHIA and VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), are pleased to announce that they have entered into a definitive purchase agreement (the “Purchase Agreement”) pursuant to which BriaPro has agreed to purchas...

February 18, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch